CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study

AINA HE1, WEIXIANG QI1, YUJING HUANG1, TAO FENG1, JIE CHEN2, YUANJUE SUN1, ZAN SHEN1 and YANG YAO1

Departments of 1Oncology and 2Pathology, The Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, P.R. China

Received March 15, 2012; Accepted May 28, 2012

DOI: 10.3892/etm.2012.603

Abstract. Identifying prognostic factors for osteosarcoma (OS) aids in the selection of patients who require more aggressive management. CD133 has been found to be a prognostic factor of certain tumor types. However, the association between CD133 expression and the prognosis of OS remains unknown. In this study, we analyzed the association of CD133 expression in OS with clinical factors and overall survival, and further investigated its potential role in metastasis in vitro. We found CD133 expression in 65.7% (46/70) of OS samples using immunohistochemistry, and it was positively correlated with lung metastasis analyzed by Chi-square test (P=0.002) and shorter overall survival time using the Kaplan-Meier method compared by log-rank test (P=0.000). Multivariate analysis showed that CD133 expression was an independent prognostic factor of patients with OS. To test for direct participation of CD133, we separated CD133+ and CD133− cells in the MG63 cell line using magnetic-activated cell sorting and found that CD133+ cells were more active in migration by scratch wound-healing assay and invasion by Matrigel invasion assay compared with CD133− cells. Elevated mRNA expression of the stemness gene octamer-binding transcription factor 4 (Oct-4) and NANOG, and the metastasis-related receptor C-X-C chemokine receptor type 4 (CXCR4) were also found in CD133+ cells by reverse transcription-polymerase chain reaction. Thus, expression of CD133 was correlated with lung metastasis and poor prognosis in OS patients. CD133+ cells may be a type of cancer stem cell with high expression of self-renewal capacity and metastasis-related genes.

Introduction

Osteosarcoma (OS), as a malignant primary bone tumor, typically occurs in children, adolescents and young adults (1), with an age-standardized incidence of approximately 5 per million per year (2). Despite the improvement of multidisciplinary treatment, including aggressive surgical resection and intensive multiagent chemotherapy and radiotherapy (3), 30% of patients with localized disease and 80% with metastatic disease at diagnosis will relapse (4,5), and 40% of patients succumb to lung metastases (6). Identifying prognostic factors in OS aids selection of those patients for more aggressive management at early time points (7-9).

CD133, also known as prominin-1, is a member of the pentaspan transmembrane glycoproteins (10,11). Although it was initially expressed in hematopoietic stem cells, CD133 presentation was also found in various solid tumors, such as hepatocarcinoma (12), melanoma (13) and synovial sarcoma (14), but not in OS to date. However, Tirino et al (15) identified CD133+ cells within OS cell lines SAOS2, U2OS and MG-63 in 2008, and other investigators (16,17) have confirmed their presence in various OS cell lines. Furthermore, we investigate the expression of CD133 in OS tissues in this study.

In addition, CD133 has been found to be a prognostic factor for certain cancer types. Several studies have reported that the presence of CD133 in various tumors was correlated with poor prognosis. Song et al (18) found that high expression of CD133 was correlated with increased tumor grade, advanced disease stage, elevated serum α-fetoprotein levels and poor survival of patients with hepatocellular carcinoma. Similarly, Horst et al (19) found that CD133 expression was an independent prognostic marker for low survival in colorectal cancer. Furthermore, Zhang et al (20) reported that CD133 expression was a predictor of poor response to chemotherapy and of reduced disease-free survival time for patients with ovarian cancer. However, Qin et al (21) revealed that CD133 was not associated with cisplatin-based chemotherapy resistance or shorter overall survival of patients with advanced serous ovarian cancer. Moreover, Fan et al (22) demonstrated that CD133-negative expression correlated with poor prognosis, whereas CD133-positive expression predicted favorable outcome in cholangiocarcinoma patients.

To date, the association between CD133 expression and prognosis of OS remains unknown. In this study, we analyzed the association of CD133 expression in OS with clinical factors and overall survival, and further investigated its potential role in metastasis in vitro.

Key words: osteosarcoma, CD133, prognosis, lung metastasis

Correspondence to: Dr Yang Yao, Department of Oncology, The Sixth People’s Hospital, Shanghai Jiao Tong University, 600 Yishan Road, Shanghai 200233, P.R. China
E-mail: ai_na_he@yahoo.com

EXPERIMENTAL AND THERAPEUTIC MEDICINE 4: 435-441, 2012
Materials and methods

Patient data collection. Paraffin-embedded OS sections from 70 patients who were diagnosed with primary OS and had undergone initial surgery at the Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China, between January 2002 and January 2010 were obtained from the Department of Pathology for immunohistochemical staining. Follow-up information was updated through December 31, 2011, by reviewing medical records and telephone contact. The use of tissue blocks and the chart reviews were approved by the Ethics Committee of the Sixth People's Hospital, Shanghai JiaoTong University. The relevant clinical data included gender, age, tumor location, tumor size, Ennecking stage, local recurrence status, lung metastasis status and overall survival. Overall survival was calculated as the time from the date of diagnosis to the date of death or the date of last follow-up if the patient was still surviving.

Immunohistochemistry. Paraffin sections (4-µm thickness) were deparaffinized and treated with 3% hydrogen peroxide for 10 min to quench the endogenous peroxidase activity. Antigenic retrieval was performed by submerging in citric acid (pH 6.0) and microwaving. The slides were then allowed to cool at room temperature, followed by incubation in normal goat serum for 1 h to block nonspecific binding, then incubated overnight at 4°C using CD133 antibody (1:100, Abcam, Hong Kong), and examined using HRP Envision Systems (Dako, Shanghai, China). Rabbit IgG was used as the primary antibody for the negative control. Finally, the sections were visualized after counterstaining with hematoxylin. Each section was evaluated by three independent pathologists without knowledge of the clinical case features. The whole sections were screened for CD133 expression under x100 magnification.

Flow cytometry. To measure the proportions of CD133+ cells in the human MG63 OS cell line, cells were detached using 0.02% EDTA in phosphate-buffered saline (PBS), counted and washed in PBS. At least 10^5 cells were incubated with CD133/2(293C3)-APC (1:100; Miltenyi Biotec, Auburn, CA, USA) at 4°C for 30 min in the dark. After washing steps, the labeled cells were analyzed by flow cytometry (Beckman Coulter, Brea, CA, USA).

Magnetic-activated cell sorting (MACS). CD133+ cells in MG63 were magnetically labeled using a CD133 microbead kit (Miltenyi Biotec) as described in the manufacturer's instructions. Briefly, 10^6 cells were dissociated and resuspended in 300 µl PBS supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA (pH 7.2). CD133 microbeads were used for positive selection by MACS cell separation using two MACS MS columns consecutively. After separation by MACS, aliquots of the positive and negative sorted populations were evaluated for purity by flow cytometry. Purities ranged from 90 to 95% for positive and from 89 to 99% for negative populations. During the experiment, 4-6 passages of the sorted cells were used.

Immunofluorescence staining. CD133+ and CD133- cells cultured in 6-well plates were fixed in 4% paraformaldehyde for 30 min at 4°C, washed in PBS, treated with PBS supplemented with 1% BSA for 1 h at room temperature and then stained with CD133 antibody (1:100) at 4°C overnight. Goat anti-rabbit IgG-FITC (CW Biotec, Beijing, China) was used as a secondary antibody, the nuclei were stained with DAPI. Cells were then washed and observed under a fluorescence microscope (Olympus BX41, Tokyo, Japan).

Western blotting. Protein (50 µg) prepared from MG-63, CD133+ and CD133- cells were loaded per lane and electrophoresed in SDS-PAGE, and then transferred onto polyvinylidene difluoride Immobilon-P membranes (Bio-Rad, Hercules, CA, USA) using a transblot apparatus (Bio-Rad). The membranes were blocked in 10 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl and 0.05% Tween-20 (TBST) with 5% (w/v) non-fat milk at room temperature, followed by overnight incubation at 4°C with primary antibodies diluted in TBST [1:1000 for CD133; 1:1000 for β-actin (CW Biotec)]. After washing with TBST, the membranes were incubated for 1 h with an HRP-conjugated secondary antibody diluted 1:5000 in TBST, and the labeled proteins were detected using the enhanced chemiluminescence reagents and exposed to the film.

Scratch wound-healing assay. Migratory ability was determined using a scratch wound-healing assay. CD133+ and CD133- cells were seeded and grown to confluence, and then scratches were made on the cell layer with a pipette tip running across the dishes. Plates were washed twice with fresh medium to remove non-adherent cells. Locations (n=3-4) were visualized and photographed at 0 and 24 h under a phase-contrast inverted microscope (Olympus BX41, Japan). The distance between the two edges of the scratch was measured (23).

Matrigel invasion assay. Cell invasion was performed using 24-well Transwells (8-mm pore size; Corning, NY, USA) coated with Matrigel (1 mg/ml; BD, NJ, USA) in triplicate. CD133+ and CD133- cells (10^5 per well) were seeded in the upper chambers in culture media containing 0.2% fetal bovine serum (FBS), and the lower chambers were filled with 500 µl 10% FBS medium to induce cell migration. Following incubation for 24 h, cells inside the chamber were wiped off with a cotton swab, invading cells were stained with Giemsa (Lexus Biotec, Shanghai, China) and examined using microscopy (Olympus BX41). Cells in at least six random microscopic fields (x200 magnification) were counted to determine relative invasive potential.

Reverse transcription-polymerase chain reaction (RT-PCR). Total cellular RNA of CD133+ and CD133- cells was extracted using TRIzol reagent (Ambion, Austin, TX, USA) and treated with RNase-free DNase (DNase I, Ambion) to remove potential genomic DNA contaminants. Total RNA (1 µg) was reverse-transcribed with the RETROscript™ Two-Step RT-PCR system (Ambion). Reactions were performed according to the manufacturer's instructions using SYBR green PCR supermix (Sangon Biotech, Shanghai, China) in a single-color RT-PCR detection system (Stratagene, Santa Clara, CA, USA). The gene expression levels (mRNA) of octamer-binding transcription factor 4 (Oct-4), NANOG, and metastasis-related receptor for 436 HE et al. CD133 AS A POOR PROGNOSTIC FACTOR OF OSTEOSARCOMA
C-X-C chemokine receptor type 4 (CXCR4) were normalized to that of the GAPDH transcript. Sequences for mRNAs from the nucleotide data bank (National Center for Biotechnology Information, USA) were used to design primer pairs for RT-PCR reactions (Table I).

Correlation between CD133 expression and clinicopathological characteristics. CD133 stained the cytoplasm and membrane of tumor cells and representative images of immunostaining of OS tissues are shown in Fig. 1. Cases were defined as CD133-positive if CD133 staining was detected in >10% of the entire tumor area (21,24).

As shown in Table II, there were equal numbers of male and female patients, and 29 (41.4%) patients were older than 18 years of age. Tumors were located in axial (1/70), upper limb (5/70) and lower limb (64/70) locations. In total, 20 (28.6%) and 54 (77.1%) patients had local recurrence and lung metastases, respectively. Regarding Ennecking staging, 58 patients were at stage II and 12 at stage III. Over the course of the study, 63 patients succumbed to tumor-related causes. The median overall survival of patients was 20.0 months [95% confidence interval (CI), 16.6-23.4 months].

Correlation between CD133 expression and clinicopathological characteristics. CD133 stained the cytoplasm and membrane of tumor cells and representative images of immunostaining of OS tissues are shown in Fig. 1. Cases were defined as CD133-positive if CD133 staining was detected in >10% of the entire tumor area (21,24).

As shown in Table II, CD133 expression was found in 46/70 (65.7%) of OS samples. Of the 54 patients who developed lung metastasis, 40 cases were in the CD133-positive group, whereas only 14 cases were in the negative group (P=0.002), indicating that CD133 expression was positively correlated with lung metastasis as analyzed by the Chi-square test. However, no significant association was observed between CD133 expres-
Correlation between CD133 expression and prognosis of OS patients. At the cut-off date, the median overall survival was significantly shorter in the CD133-positive group compared with the CD133-negative group (34.0 months; 95% CI, 16.0-51.9 vs. 15.0 months; 95% CI, 11.3-18.7; P=0.000) (Fig. 2). Univariate survival analysis showed that the significant prognostic factors were tumor size, local recurrence, lung metastasis and expression of CD133. Multivariate analysis showed that the CD133 expression and tumor size were independent prognostic factors of patients with OS (Table III).

Identification of CD133+ and CD133− cells. The patient data showed that expression of CD133 was related with lung metastasis in OS. To investigate the potential mechanisms, we sorted the OS cell line MG-63 for CD133+ and CD133− populations using MACS, and further confirmed our results using immunofluorescence staining and western blotting (Fig. 3).
Migratory ability of CD133\(^+\) and CD133\(^-\) cells. Migratory ability of the CD133\(^+\) and CD133\(^-\) cell populations was examined using a wound-healing assay (Fig. 4). Following incubation of physically wounded cells for 24 h, CD133\(^+\) cells were found to have traveled a significantly longer distance than CD133\(^-\) cells (P<0.05). The percentages of wound width were 32.00±6.11 and 54.67±5.21\%, respectively.

Invasiveness of CD133\(^+\) and CD133\(^-\) cells. To analyze invasiveness of the CD133\(^+\) and CD133\(^-\) cell populations, we performed Transwell invasion assays using cell culture inserts covered with extracellular matrix components. Cells (5.25±0.63 per field) traveled through the membranes in the CD133\(^+\) group, compared to only 1.50±0.29 cells per field in the CD133\(^-\) group (P<0.05) (Fig. 5).

mRNA expression of Oct-4, NANOG and CXCR4. As CD133 has been considered to be a cancer stem cell marker in several tumor types, we examined mRNA expression of the stemness gene Oct-4, NANOG and metastasis-associated receptor CXCR4 using RT-PCR in the CD133\(^+\) population and its counterpart CD133\(^-\) cells. The results showed that mRNA expression was significantly higher in the CD133\(^+\) population (Fig. 6).
Discussion

OS is a highly aggressive tumor, comprising approximately 20% of all bone tumors and 5% of pediatric tumors (25). However, our current understanding of OS etiology is limited. Previous studies have shown that many tumors contain a small population of cells termed cancer stem cells (CSCs), which are responsible for tumor progression, metastasis, recurrence and resistance to chemotherapy and radiation treatments (26,27). While the experimental evidence for the existence of CSCs was first proposed for hematological malignancies, more recently CSCs have been observed in solid tumors, including breast, brain, pancreatic and bone cancers (28). The existence of CSCs in primary OS and cell lines derived from human OS was previously demonstrated (15,29).

CD133 has been considered as a CSCs marker in a number of tumor types (28,30,31), such as colorectal, brain, prostate, pancreatic and gastric cancers, and also in OS. Subsequent studies have confirmed that CD133+ cells from OS cell lines showed stem-like features including high proliferation rate, cells detected in the G2/M phase of the cell cycle and Ki-67 positivity (15). In our patient data, we found that CD133 was a worse prognostic factor for OS and lung metastasis. In vitro, we found that CD133+ cells efficiently invaded and migrated, according to high expression of Oct-4, NANOG and CXCR4. These findings support the proposed link between CD133 and CSCs.

Oct-4, also known as Oct-3, Oct-3/4 and POU5F1, is one of the earliest transcription factors expressed in the embryo, and has been identified as fundamental to the maintenance of pluripotency and self-renewal in embryonic stem cells and primordial germ cells (32,33). NANOG is also a homeodomain transcription factor thought to be a key factor in sustaining the pluripotency of embryonic stem cells (34). A recent study of Oct-4 and NANOG in OS demonstrated that the two markers were highly expressed in CSCs, which suggests that these transcription factors play a role in sarcoma stem cell biology (35). CXCR4, a chemokine receptor in the GPCR gene family, has been proven to play an essential role in the metastasis of CSCs (36). OS stem cells were found to express more CXCR4 than normal tumor cells (37).

In conclusion, our findings reveal for the first time that high expression of CD133 in OS tissues indicates a high lung metastasis risk and short survival time in OS patients. CD133+ cells were more active in invasion and migration than CD133− cells, in accordance with higher expression of Oct-4, NANOG and CXCR4. These findings support the proposed link between CD133 and CSCs. However, further animal experiments using in vivo cell xenografts are warranted to confirm this. Prognostic judgment in order to improve the effect of treatment on OS and more suitable treatment strategies including the application of CD133 target gene therapy could be accomplished according to the expression status of CD133.

Acknowledgements

The study was supported by grants from the National Natural Science Foundation of China (no. 81001191 and 81172105) and Science and Technology Commission of Shanghai, China (no. 10PJ1408300 and 09140902200).

References

1. Arndt CA and Crist WM: Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341: 342-352, 1999.
2. Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res 152: 3-13, 2009.
3. Ozaki T, Flege S, Kervic M, et al: Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21: 334-341, 2003.
4. Sæter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal NL and Solheim OP: Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 75: 1084-1093, 1995.
5. Tabone MD, Kaliﬁa C, Rodary C, Raquín M, Valente-Couanet D and Lemerle J: Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 12: 79-82, 1994.
6. Ham SJ, Schraﬀordt Koops H, van der Graaf WT, van Horn JR, Postma L and Hoekstra HJ: Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol 24: 584-600, 1998.
7. Lin F, Zheng SE, Shen Z, et al: Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma. Med Oncol 28: 649-653, 2010.
8. Lee JA, Kim MS, Kim DH, et al: Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer 50: 195-200, 2008.
9. Yang J, Yang D, Cogswell D, et al: APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat 9: 161-169, 2010.
10. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 3002-3012, 1997.
11. Weigmann A, Corbeil D, Hellwig A and Hutner WB: Prominin, a novel microvilli-speciﬁc polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 94: 12425-12430, 1997.
12. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450, 2007.
13. Monzani E, Fucchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43: 935-946, 2007.
14. Terry J and Nielsen T: Expression of CD133 in synovial sarcoma. Appl Immunohistochem Mol Morphol 18: 159-165, 2009.
15. Tirino V, Desiderio V, d’Aquino R, et al: Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3: e3469, 2008.
16. Li J, Liu W, Zhao K, et al: Diallysyl trisulfide reverses drug resistance and lowers the ratio of CD133+ cells in conjunction with methotrexate in a human osteosarcoma drug-resistant cell subline. Mol Med Rep 2: 245-252, 2009.
17. Veselska R, Hermanova M, Loja T, et al: Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines. BMC Cancer 8: 300, 2008.
18. Song W, Li H, Tao K, et al: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218, 2008.
19. Horst D, Kriegl L, Engel M, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
20. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I and Liu J: CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 25: 456-464, 2011.
21. Qin Q, Sun Y, Fei M, et al: Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Neoplasma 58: 1242-1252, 2011.
22. Fan L, He F, Liu H, et al: CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer 11: 320, 2011.
23. Li S, Li Z, Guo F, et al: mir-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci 18: 24, 2011.
24. Kojima M, Ishii G, Atsumi N, Fuji S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99: 1578-1583, 2008.
25. Tang N, Song WX, Luo J, Haydon RC and He TC: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466: 2114-2130, 2008.
26. Wion D and Berger F: Cancer stem cells. N Engl J Med 355: 2703; author reply 2703, 2006.
27. Pardal R, Clarke MF and Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895-902, 2003.
28. Liu B, Ma W, Jha RK and Gurung K: Cancer stem cells in osteosarcoma: recent progress and perspective. Acta Oncol 50: 1142-1150, 2011.
29. Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976, 2005.
30. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
31. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
32. Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24: 372-376, 2000.
33. Looijenga LH, Stoop H, de Leeuw HP, et al: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 63: 2244-2250, 2003.
34. Mitsui K, Tokuzawa Y, Itoh H, et al: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642, 2003.
35. Wang L, Park P and Lin CY: Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 8: 543-552, 2009.
36. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
37. Adhikari AS, Agarwal N, Wood BM, et al: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70: 4602-4612, 2010.